Why the study?
Antithrombotic management following surgical or transcatheter bioprosthetic heart valve replacement remains challenging.
What is the optimal antithrombotic strategy in patients with atrial fibrillation and bioprosthetic heart valves?
What is the optimal antithrombotic strategy in patients with atrial fibrillation and bioprosthetic heart valves?
This review highlights that while NOACs are a safe and effective alternative to VKAs for patients with surgical bioprosthetic valves and atrial fibrillation, their routine use after TAVI without an established indication for anticoagulation is associated with worse outcomes.
Antithrombotic management after BHV replacement remains challenging; leaves open optimal regimens especially in AF.
The antithrombotic management of patients after surgical or transcatheter bioprosthetic heart valves (BHVs) replacement is still challenging. Our review aims to describe the current evidence on the best antithrombotic strategy among patients undergoing BHVs replacement (surgical or transcatheter) and/or valve repair, with particular attention to those with atrial fibrillation.
No takes yet. Share an insight, caveat, or question.
A 2022 study conducted a review in Atrial fibrillation and bioprosthetic heart valves. Non-vitamin K antagonist oral anticoagulants (NOACs) vs. Vitamin K antagonists (VKAs) was evaluated.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: